Cytosomatic Labs is privately funded and research-only. The work below is where that capital is committed today — the neuroscience questions we have chosen to resource, the stage each one sits at, and what is actually being built. We are not soliciting funding, and we are not hiring at this time.
CSL-R-01Assay development
Neurodiagnostics
Neurodegenerative cohort profiling
We are funding high-dimensional neural and neuroimmune profiling of well-phenotyped neurodegenerative cohorts, building panel design, instrument time and analysis capacity in-house so patient state can be described at mechanism level rather than by symptom label.
High-dimensional profiling12 months
Where the investment goes
01Multi-parameter cytometry and transcriptional panel development
02Longitudinal sample handling and annotation infrastructure
03Statistical stratification models validated across cohorts
CSL-R-02Discovery / preclinical
Neural cell therapy
Neural construct validation
Capital is directed at benchmarking delivery chemistries for neural cell-therapy constructs in primary human cells and neural co-cultures, with every comparative result recorded — favourable or not — as part of the internal validation record.
Delivery chemistry benchmarking6 months per cycle
Where the investment goes
01Construct design and transduction efficiency studies
02Vector-free delivery evaluation in donor-derived co-cultures
03Engineered safety-switch and cytokine-release characterisation
CSL-R-03Exploratory
Neurorestoration
Neurorestoration protocol development
A milestone-structured investment into ex vivo expansion and differentiation protocols for depleted neural and supporting cell populations, measured by restored neural function rather than restored cell counts alone.
Functional recovery readouts18 months
Where the investment goes
01Ex vivo expansion and differentiation protocol work
02Functional recovery assay development
03Durability and neuroinflammatory risk modelling
CSL-R-04Ongoing
Research governance
Clinical relevance review
We invest in structured review of our own study designs and endpoints by practising neurologists, neuroimmunologists and neuroradiologists before bench time is committed, so resources go to questions that matter clinically.
Study design scrutinyQuarterly
Where the investment goes
01Quarterly design and endpoint review cycles
02Pre-registration of study designs before data collection
03Orthogonal replication of every key result
CSL-R-0101 / 04
NeurodiagnosticsAssay development
How we allocate
Research questions get funded before they get promoted
Every programme above is documented before data collection begins, replicated with an orthogonal method, and retained whether the result is positive or null. Nothing on this page describes an approved therapy or a clinical service.